Screening for prostate cancer: Estimating the magnitude of overdetection

CMAJ. Canadian Medical Association Journal

Volumn 159, Issue 11, 1998, Pages 1368-1372

  McGregor, Maurice ^a,b   Hanley, James A ^a,b   Boivin, Jean François ^a,c   McLean, Richard George ^d  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Western Nuclear Medicine   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CALCULATION; CANADA; CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; CAUSE OF DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

EID: 0032409148     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Coley CM, Barry MJ, Fleming C, Fahs M, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits and costs. Ann Intern Med 1997;126:468-79.
2. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Executive summary. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997;1(2):1-4.
3. Hirst GHL, Ward JE, Del Mar CB. Screening for prostate cancer: the case against. Med J Aust 1996;164(5):285-8.
4. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales. Br J Urol 1997;79(Suppl 3):1-32.
5. American College of Physicians. Screening for prostate cancer (clinical guidelines, part III).Ann Intern Med 1997;126:480-4.
6. Woolf SH. Should we screen for prostate cancer? [editorial] BMJ 1997;314: 989-90.
7. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-8.
8. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long-term results. J Urol 1994;152:1781-5.
9. Statistiques sur les causes de mortalité au Québec - 1971, 1975-1993. Québec: Ministère de la Santé et des Services sociaux; 1995.
10. Carter HB, Pearson JD, Metter J, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 1992;267:2215-20.
11. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
12. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 33:996-1004.
13. Catalora WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
14. Pearson JO, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152(Part 2):1743-8.
15. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
16. Cohen RJ, Haffejee Z, Steels GS, Nayler SJ. Advanced prostate cancer with normal serum prostate-specific antigen values. Arch Pathol Lab Med 1994;118:1123-6.
17. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309-15.
18. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-7.
19. Atkins D. Prostate cancer screening [letter]. JAMA 1997;277:299-300.
20. Australian Health Technology Advisory Committee. Prostate cancer screening. Canberra: Australian Government Publishing Service; 1996.
21. Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA 1996;276:1976-9.
22. Schröder FH. Screening, early detection, and treatment of prostate cancer: a European view. Urology 1995;46(3 Suppl A):62-70.
23. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
24. Fowler FJ, Roman A, Barry MJ, Wasson J, Lu-Yao G, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: the National Medicare experience: 1988-90 (updated June 1993). Urology 1993;42:622-9.
25. Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson M. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission of Cancer. J Urol 1994;152(Part2):1817-9.
26. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993;2:487-93.
27. Schmidt JD, Mettlin CJ, Natarajan N, Peace BB, Beart RW Jr, Wnchester DP, et al. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Ural 1986;136:416-21.
28. World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death. Geneva: WHO; 1977.
29. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer: a prospective, population-based study in Sweden. JAMA 1997;277:467-71.
30. Percy C, Stanek E, Gloccklcr L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health 1981;71:242-50.
31. Goldacre MJ. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J Epidemiol Community Health 1993;47:491-6.
32. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
33. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
34. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, et al. Optimized strategy for detection of early prostate cancer: role of presceening with prostate-specific antigen. Clin Invest Med 1993;16:425-39.